The Last Observed Positive Cannabis Urine Test Is Not Always the Clearance Date
A study’s last recorded positive cannabis urine test may mark the end of observation rather than the end of excretion. In a monitored-abstinence study, some participants were still testing positive when their residential follow-up ended.
A strong design for studying residual excretion
Sixty cannabis users stayed on a closed research unit with continuous medical surveillance for periods of up to 30 days. Researchers collected 6,158 urine specimens, screened them at a 50 ng/mL cutoff and quantified THC-COOH using a separate GC–MS procedure.
The study measured urinary metabolite elimination, not whole-blood parent THC or driving performance. Continuous observation strengthened the conclusion that later positive specimens could occur without new cannabis access during the residential stay.
Follow-up length limits the meaning of ‘last’
Participants were grouped by the creatinine-normalized THC-COOH concentration in their first specimen. In the highest initial group, 13 of 20 participants remained positive on their final observation day; four were still positive at approximately 30 days.
For those people, the data did not observe a later sustained negative period. Their final recorded positive is therefore a lower bound on how long positivity persisted under the study conditions, not a demonstrated clearance date.
One negative result did not end the detection period
Positive and negative screening results could alternate during abstinence. Initial normalized concentration was significantly associated with first-negative and last-positive timing, but individual trajectories varied substantially.
Forty percent of participants reached their maximum creatinine-normalized concentration after admission, sometimes nearly three days later. Creatinine adjustment reduced dilution-related variability; it did not force each person’s metabolite curve to decline monotonically.
Applying the evidence to a series of tests
Keep the observation window, collection intervals, screening cutoff and confirmatory analyte separate. The study’s screening decision used ng/mL, while initial grouping used metabolite concentration per milligram of creatinine. Those units should not be substituted for one another.
The results do not establish one universal number of days after which every positive proves renewed use. They show why a serial interpretation must account for residual excretion and incomplete follow-up. Neither a last positive nor an earlier negative independently determines impairment at an event.
Related: Interpreting THC concentration and impairment.
Primary research
Urinary Elimination of 11-Nor-9-carboxy-Δ9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence. DOI: 10.1093/jat/32.8.562.
